- Product Overview: First in class SGK agonist for neurodegenerative diseases
- Primary Indications; Rare diseases of the eye – Neuromyelitis Optica, (NMO) & acute optical neuritis (AON). Orphan conditions
- Secondary Indications: Multiple Sclerosis, including progressive (SPMS and PPMS)
- Core differentiator(s):
- Primary neuroprotective agent which prevents axonal loss and neuronal death in several animal models driven by different mechanisms of damage, including demyelination, inflammation and hypertension;
- Promotes remyelination
- Development stage; Phase 1
- Company; Bionure; bionure.com
- Opportunity: Available for license collaboration and investment; (Series B round in progress)